A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Clemons, M
  • Dranitsaris, G
  • Ooi, WS
  • Yogendran, G
  • Sukovic, T
  • Wong, BYL
  • Verma, S
  • Pritchard, Kathleen
  • Trudeau, M
  • Cole, DEC

publication date

  • December 1, 2006